Furthermore, recent experimental approaches such as Lu Wang’s ECM deprivation system effectively reversed RCC’s anoikis resistance and enhanced sensitivity to doxorubicin chemotherapy [64], while Peng Zhang’s team found that silencing TrkB improved sorafenib efficacy [65]. The gene discussed is NTRK2; the disease is renal cell carcinoma.